A liquid biopsy-based proteomic assay to identify circulating tumor cell (CTC) –derived druggable targets in cancer patients. Assessing the impact of PTEN loss on outcomes in high-/very high-risk, ...
For example, around 15- 20% of patients with prostate cancer lack the tumour suppressor gene PTEN, which result in disease that is difficult to treat. PTEN serves largely as a biomarker of ...
Previous research has shown that this pathway, called the PI3K-AKT pathway, is frequently mutated in prostate cancer. Although the most common mutation, in a gene called Pten, had already been ...
Estimates for the frequency of PTEN mutations in prostate cancer vary widely, between around 15% and 60%, depending on the type and stage of the disease, but testing for the biomarker isn't ...
Assessing the impact of PTEN loss on outcomes in high-/very high-risk, advanced hormone-sensitive prostate cancer patients: Institutional retrospective study. Grade and volume progression and its ...
UK-based pharmaceutical company AstraZeneca has reported positive results from its Phase III CAPItello-281 trial, which evaluated Truqap combined with abiraterone and androgen deprivation therapy ...
Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement next-generation sequencing (NGS) for precise patient stratification and ...
Results of a study led by the Vall d'Hebron Institute of Oncology (VHIO) support the feasibility of using RAD51 testing to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results